Adhera Therapeutics, Inc.
Adhera Therapeutics, Inc. (ATRX): 3 pipeline candidates · 3 clinical trials. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E -1.00 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Adhera Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$722
Cash
—
Quarterly Burn
$29K
Runway
—
Revenue
—
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Adhera Therapeutics, Inc.'s pipeline?
Adhera Therapeutics, Inc. (ATRX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Adhera Therapeutics, Inc.'s lead drug candidate?
Adhera Therapeutics, Inc.'s most advanced tracked candidate is MLR-1019 (Phase 2) for Parkinson's disease (addresses both movement and non-movement aspects of PD).
What is Adhera Therapeutics, Inc.'s market capitalization?
Adhera Therapeutics, Inc.'s market capitalization is approximately $722.
Who is the CEO of Adhera Therapeutics, Inc.?
Chief Executive Officer is the chief executive officer of Adhera Therapeutics, Inc. (ATRX).
Get the full picture on Adhera Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.